Albertini M, Zuleger C, Ranheim E, Shiyanbola O, Sondel P, Morris Z
Melanoma Res. 2024; 34(4):307-318.
PMID: 38768442
PMC: 11444423.
DOI: 10.1097/CMR.0000000000000975.
Rotta G, Gilardoni E, Ravazza D, Mock J, Seehusen F, Elsayed A
EMBO Mol Med. 2024; 16(4):904-926.
PMID: 38448543
PMC: 11018789.
DOI: 10.1038/s44321-024-00034-0.
Yang R, Kuznetsov I, Ranheim E, Wei J, Sindiri S, Gryder B
Clin Cancer Res. 2020; 26(13):3296-3306.
PMID: 32152202
PMC: 7334053.
DOI: 10.1158/1078-0432.CCR-19-3294.
Hutmacher C, Gonzalo Nunez N, Liuzzi A, Becher B, Neri D
Cancer Immunol Res. 2019; 7(4):572-583.
PMID: 30782667
PMC: 6978143.
DOI: 10.1158/2326-6066.CIR-18-0566.
Albertini M, Yang R, Ranheim E, Hank J, Zuleger C, Weber S
Cancer Immunol Immunother. 2018; 67(10):1647-1658.
PMID: 30073390
PMC: 6168354.
DOI: 10.1007/s00262-018-2223-z.
Cytokines in the Treatment of Cancer.
Conlon K, Miljkovic M, Waldmann T
J Interferon Cytokine Res. 2018; 39(1):6-21.
PMID: 29889594
PMC: 6350412.
DOI: 10.1089/jir.2018.0019.
Cytokines in Cancer Immunotherapy.
Waldmann T
Cold Spring Harb Perspect Biol. 2017; 10(12).
PMID: 29101107
PMC: 6280701.
DOI: 10.1101/cshperspect.a028472.
The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy.
Waldmann T
Cancer Immunol Res. 2015; 3(3):219-27.
PMID: 25736261
PMC: 4351780.
DOI: 10.1158/2326-6066.CIR-15-0009.
Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma.
Pedretti M, Verpelli C, Marlind J, Bertani G, Sala C, Neri D
Br J Cancer. 2010; 103(6):827-36.
PMID: 20736949
PMC: 2966626.
DOI: 10.1038/sj.bjc.6605832.
Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma.
Hank J, Gan J, Ryu H, Ostendorf A, Stauder M, Sternberg A
Clin Cancer Res. 2009; 15(18):5923-30.
PMID: 19737959
PMC: 2745522.
DOI: 10.1158/1078-0432.CCR-08-2963.
High efficient mammalian expression and secretion of a functional humanized single-chain Fv/human interleukin-2 molecules.
Shen Y, Wang X, Wang X, Chen Z, Shen X, Zhao C
World J Gastroenterol. 2006; 12(24):3859-65.
PMID: 16804971
PMC: 4087934.
DOI: 10.3748/wjg.v12.i24.3859.
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
Osenga K, Hank J, Albertini M, Gan J, Sternberg A, Eickhoff J
Clin Cancer Res. 2006; 12(6):1750-9.
PMID: 16551859
PMC: 2587020.
DOI: 10.1158/1078-0432.CCR-05-2000.
Anti-Her-2/neu-IL-2 or heregulin-IL-2 fusions proteins redirect non-tumor specific CTL to the tumor site for tumor eradication.
Lustgarten J
Cancer Immunol Immunother. 2003; 52(12):751-60.
PMID: 12827309
PMC: 11034242.
DOI: 10.1007/s00262-003-0410-y.
Specific enzyme-linked immunosorbent assays for quantitation of antibody-cytokine fusion proteins.
Gan J, Kendra K, Ricci M, Hank J, Gillies S, Sondel P
Clin Diagn Lab Immunol. 1999; 6(2):236-42.
PMID: 10066660
PMC: 95693.
DOI: 10.1128/CDLI.6.2.236-242.1999.
Protein kinase C in IL-2 signal transduction.
Lu Y, Durkin J
Immunol Res. 1997; 16(4):355-74.
PMID: 9439760
DOI: 10.1007/BF02786399.
